Reducing the Frequency and Severity of Exacerbations of Chronic Obstructive Pulmonary Disease
- 1 April 2004
- journal article
- review article
- Published by Oxford University Press (OUP) in Proceedings of the American Thoracic Society
- Vol. 1 (2) , 121-124
Abstract
Exacerbations contribute significantly to impaired health status in chronic obstructive pulmonary disease (COPD), but current therapy can prevent these episodes. Immunization against, for example, influenza offers specific prophylaxis for a minority of episodes. Pulmonary rehabilitation reduces hospital attendance, but its effect wanes. Inhaled bronchodilators such as tiotropium produce similar reductions in exacerbation frequency. Database studies show an association between prescription of inhaled corticosteroids and reduced hospitalization in the older population, a finding confirmed by randomized trials in patients with an FEV1 of less than 50% predicted. Three 1-year randomized clinical trials studied the effect of combining a long-acting β-agonist with an inhaled corticosteroids. In these studies, exacerbation frequency was lower with therapy than placebo. Combination therapy had a similar effect to its monocomponents in the trial of inhaled steroids and long-acting β agonists study using salmeterol and fluticasone. However, when patients with more severe COPD (an FEV1 of less than 36% predicted) were studied using a combination of budesonide and formoterol, a clear improvement was seen in the overall exacerbation rate compared with the β-agonist alone. In addition, the time to first exacerbation was increased compared with either drug alone. Health status changes mirrored these effects. In summary, combination therapy can effectively prevent exacerbations in patients with more advanced COPD.Keywords
This publication has 25 references indexed in Scilit:
- Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax, 2003
- Reduction of Hospital Utilization in Patients With Chronic Obstructive Pulmonary DiseaseA Disease-Specific Self-management InterventionArchives of internal medicine (1960), 2003
- Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialThe Lancet, 2003
- Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbationsThorax, 2002
- Use of a Long-acting Inhaled β2-Adrenergic Agonist, Salmeterol Xinafoate, in Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Time Course and Recovery of Exacerbations in Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2000
- The Risk of Myocardial Infarction Associated with Inhaled β -Adrenoceptor AgonistsAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trialThe Lancet, 2000
- Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 1998